Drug intelligence / Profile preview

SIS021

Development stage: Unknown
Lead developer: Nanjing Sanhome Pharmaceutical
Administration: Parenteral

Overview

SIS021 is an investigational therapeutic candidate being developed by Nanjing Sanhome Pharmaceutical for the treatment of solid tumors, including ovarian cancer, breast cancer, and lung cancer. The drug is currently in early-stage development, transitioning between preclinical evaluation and Phase 1 clinical trials. Detailed information regarding its specific molecular target and modality has not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on SIS021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIS021.

Explore the full profile